Our Mission

Pipeline

Our Focus

We are advancing a wholly owned portfolio of oral small molecule GPCR-targeted programs focused initially on treating patients with significant unmet needs in endocrinology, immunology and inflammation, and metabolic disease.

For each program, we utilize our Native Complex Platform™ to discover a diverse portfolio of small molecules with mechanisms of action designed to have disease-modifying potential and with distinct chemical properties. We have prioritized programs that offer biomarker-driven strategies for early clinical readouts.

Pipeline

Scroll sideways to view more.

Wholly-Owned Programs

Development Status

Program / Target

Mode of Action

Therapeutic Area

Indications / US Patient Population

Discovery

IND-enabling

Phase 1

Phase 2

PTH1R Program

Hypoparathyroidism

40%

SEP-631 (MRGPRX2)

Chronic spontaneous urticaria
Other mast cell diseases

50%

TSHR Program

Graves' disease
Thyroid eye disease

20%

Research Areas:

20%

No results found.

Partnered Programs

Partner

Metabolic Programs

Metabolic Programs

Obesity and Other Cardiometabolic Diseases

0%

Undisclosed

Undisclosed

0%

No results found.

PTH1R = Parathyroid Hormone 1 Receptor
TSHR = Thyroid-Stimulating Hormone Receptor
MRGPRX2 = MAS-Related G Protein-Coupled Receptor X2
GLP-1R = Glucagon-Like Peptide 1 Receptor
GIPR = Gastric Inhibitory Polypeptide Receptor
GCGR = Glucagon Receptor

The Details

Programs
Additional Information

PTH1R Program

PTH1R Program

Oral small molecule agonist targeting PTH1R for the treatment of hypoparathyroidism that could offer a convenient, functional replacement for PTH for all hypoparathyroidism patients.

SEP-631 (MRGPRX2)

SEP-631 (MRGPRX2)

Oral small molecule negative allosteric modulator (NAM) that inhibits MRGPRX2 and could provide a differentiated treatment option for patients with chronic spontaneous urticaria (CSU) and other mast cell driven diseases.

TSHR Program

TSHR Program

Oral small molecule thyroid-stimulating hormone receptor (TSHR) NAM that could offer a novel disease-modifying treatment approach for both Graves’ Disease and Thyroid Eye Disease.

Metabolic Programs

Metabolic Programs

Partnered Programs

In addition to pursuing R&D programs that we can independently develop and commercialize, our strategy includes selectively partnering programs that may benefit from the development expertise, commercial infrastructure, and financial support of a strategic partner.

No results found.

The Details

Publications